Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1862P - Atezolizumab and severe cutaneous adverse reactions: Data mining of the FDA Adverse Event Reporting System (FAERS) database

Date

16 Sep 2021

Session

ePoster Display

Topics

Management of Systemic Therapy Toxicities;  Supportive Care and Symptom Management

Tumour Site

Presenters

Alessandro Pecere

Citation

Annals of Oncology (2021) 32 (suppl_5): S1237-S1256. 10.1016/annonc/annonc701

Authors

A. Pecere1, G.C. Bisinella2

Author affiliations

  • 1 Department Of Pharmaceutical Science, Università degli Studi di Milano, 20122 - Milano/IT
  • 2 Department Of Physiology And Pharmacology, Università degli Studi di Roma "La Sapienza", 00185 - Roma/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1862P

Background

Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1, used in the treatment of different cancer types. A warning has been issued by the European Medicine Agency regarding the risk of Steven-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with atezolizumab. Along with acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS), SJS and TEN are classified as severe cutaneous adverse reactions (SCARs). The objective of this study was to investigate whether a disproportionally elevated signal of developing SCARs may be detected in patients treated with atezolizumab as compared to those treated with other drugs.

Methods

A retrospective analysis of spontaneously reported cases of SCARs contained in the free and publicly available FDA Adverse Event Reporting System (FAERS) database was conducted in the period 2014-2020. We calculated, as a signal of disproportionality, the reporting odds ratio (ROR), and the relative 95% confidence interval (CI), of SCARs in patients treated with atezolizumab. The signal was considered significant when the ROR lower limit of the 95% CI was > 1.

Results

A total of 13,011,377 FAERS reports were identified during the study period; 9,574 (0.07%) reports mentioned atezolizumab. There were 26,572 (0,20%) reports of SCARS of which 36 (0.14%) attributed to atezolizumab treatment: 25 SJS, 3 DRESS, 7 TEN and 1 AGEP, respectively. The majority of these reports referred to patients aged 68-85 years (47.06%) and female (58.82%). A significant signal was only detected for SJS: ROR = 4.74; 95% CI 3.20-7.03.

Conclusions

With this study we demonstrated that in patients treated with atezolizumab, SJS was the only SCAR for which a signal of disproportionate reporting was found. Although rare, SCARs are potentially fatal events and are now considered to be an identified risk for atezolizumab. It would be of interest to further analyze reports of SCARs associated with this drug, comparing signals deriving from FAERS and those deriving from the European pharmacovigilance database EudraVigilance.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

A. Pecere.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.